Tissue Regenix Group PLC Director/PDMR Shareholding (5190H)
April 06 2022 - 9:59AM
UK Regulatory
TIDMTRX
RNS Number : 5190H
Tissue Regenix Group PLC
06 April 2022
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Director/PDMR Shareholding
Tissue Regenix Group (AIM:TRX), the regenerative medical devices
company, announces it has been notified that on 5 April 2022,
Daniel Lee, Chief Executive Officer, and David Cocke, Chief
Financial Officer, both individually purchased 1,785,000 Ordinary
Shares of 0.1p each in the Company at a price of 0.44 pence per
Ordinary Share, for a total consideration of GBP7,854 each.
Following the purchase, Mr Lee holds 5,262,200 Ordinary Shares
in the Company representing 0.07% of the Company's issued share
capital and Mr Cocke holds 5,692,000 Ordinary Shares in the Company
representing 0.08% of the Company's issued share capital.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44(0)20 7710 7600
and Broker)
Ben Maddison / Nick Harland
Walbrook PR Ltd Tel: +44 (0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Daniel Lee
--------------------------------------- ---------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
--------------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------------------------- ---------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1p each
financial instrument,
type of instrument
Identification code GB00B5SGVL29
b) Nature of the transaction Purchase
--------------------------------------- ---------------------------------------
c) Price(s) and volume(s)
----------------- -----------------
Price(s) Volume(s)
----------------- -----------------
0.44p 1,785,000
----------------- -----------------
d) Aggregated information
- Aggregated volume 1,785,000
- Price GBP7,854
e) Date of the transaction 5 April 2022
--------------------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------------------- ---------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name David Cocke
--------------------------------------- ---------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------------------------- ---------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1p each
financial instrument,
type of instrument
Identification code GB00B5SGVL29
b) Nature of the transaction Purchase
--------------------------------------- ---------------------------------------
c) Price(s) and volume(s)
----------------- -----------------
Price(s) Volume(s)
----------------- -----------------
0.44p 1,785,000
----------------- -----------------
d) Aggregated information
- Aggregated volume 1,785,000
- Price GBP7,854
e) Date of the transaction 5 April 2022
--------------------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------------------- ---------------------------------------
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or damaged body structures. Current
applications address many critical clinical needs such as in sports
medicine, foot and ankle, and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, dental, and ophthalmological surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBXGDSRUGDGDL
(END) Dow Jones Newswires
April 06, 2022 09:59 ET (13:59 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024
